CG
XFOR icon

Cutler Group’s X4 Pharmaceuticals XFOR Stock Holding History

Cutler Group’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-407
Closed -$12K – 4842
2022
Q4 		$12K Buy
407
+390
+2,294% +$18.5K ﹤0.01% 2598
2022
Q3 		$0 Sell
17
-17
-50% -$587 ﹤0.01% 5615
2022
Q2 		$0 Buy
+34
New +$1.29K ﹤0.01% 5779

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's XFOR Position: Q1 2023 in Review

Cutler Group sold out of X4 Pharmaceuticals (XFOR) in Q1 2023, closing a stake of 407 shares — an estimated $12K sold.

Cutler Group first reported a position in XFOR in Q2 2022 and held it in 3 quarters. The position peaked at $12K in Q4 2022. 56 funds tracked by Wall St. Rank hold XFOR as of Q1 2023.

  • Cutler Group reported no remaining X4 Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 407 X4 Pharmaceuticals shares in Q1 2023, an estimated $12K.
  • Cutler Group first reported a position in X4 Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Cutler Group's X4 Pharmaceuticals position peaked at $12K in Q4 2022.
  • 56 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.